{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Leukemia free state"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Morphological complete remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0"}]}],"title":"Incomplete morphological complete remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Partial remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"0"}]}],"title":"Bone marrow blast response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Bone marrow minor blast response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"23.1"}]}],"title":"Peripheral blood blast response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0"}]}],"title":"Minor peripheral blood blast response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4"},{"groupId":"OG001","value":"7.7"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"61.5"}]}],"title":"Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7.7"}]}],"title":"Not Done"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6"},{"groupId":"OG001","value":"23.1"}]}],"title":"Participants with response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"The best overall clinical response was determined as per the clinical assessment done by the investigator. Responders were defined as all participants with a best clinical response of leukemia free state, morphological complete remission, incomplete morphological complete remission, partial remission, bone marrow blast response, bone marrow minor blast response, peripheral blood blast response, minor peripheral blood blast response. Participants with stable disease, progressive disease and with missing tumour assessment or who discontinued the study or who died before having their first assessment were considered as non-responders. Stable disease was defined as failure to achieve any of the above response. Progressive disease was defined as doubling of the bone marrow blast percentage from baseline in participants with \\<40% bone marrow blasts at baseline, or a 50% increase in bone marrow blast percentage from baseline in participants with \\>40% bone marrow blasts at baseline,","groups":[{"description":"Subjects with acute myeloid leukemia (AML) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\\^2.","id":"OG000","title":"AML Subjects"},{"description":"Subjects with mixed lineage leukemia gene- rearranged acute lymphoblastic leukemia (MLLr-ALL) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\\^2.","id":"OG001","title":"MLLr-ALL Subjects"}],"paramType":"NUMBER","populationDescription":"The analysis was performed in full analysis set (FAS) population, defined as all participants to whom study treatment was assigned.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 15 (Day 1 of Cycle 2), Day 22 (Day 8 of Cycle 2), Day 29(Day 1 of Cycle 9), End of treatment (up to 24 months after last dose or until death whichever occurred first)","title":"Percentage of Participants With Best Overall Response by Indication","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}